By examining samples from prior studies, NIAID-funded researchers found a way to predict if a tuberculosis patient is likely to relapse.

Friday, November 9, 2018 NIAID Now: NIAID-Funded Researchers Predict TB Relapse Risk Drug-resistant tuberculosis is a serious threat—and when TB patients relapse after standard treatment, they can spread antibiotic-resistant bacteria to other people. A new post on the NIAID Now blog explains how, by examining samples from prior studies, NIAID-funded researchers found a way to predict if a tuberculosis patient is likely to relapse. This could help healthcare providers design treatment plans which limit unnecessary antibiotics, while ensuring patients who are likely to relapse receive the treatments they need. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107